Sinobiopharma, Inc., a US-headquartered company that operates entirely in China, will co-develop, manufacture and commercialize Eplerenone, with Jiangsu Lianhuan Pharmaceuticals Co. Eplerenone is an aldosterone antagonist used as an adjunct to treat hypertension and heart failure. Sinobiopharma will receive 60% of the profits. More details....

Stock Symbol: (OTCBB: SNBP)